৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Acute bacterial skin and skin structure infections (ABSSSI)
Oral Administration\r\nMay take with or without food\r\n\r\nIV Administration\r\nAdminister as IV infusion over 1 hr\r\nDo NOT give as IV push or bolus\r\nNot for intra-arterial, IM, IT, intraperitoneal, or SC administration
Adult: 200 mg PO/IV once daily for 6 days\r\n\r\nHepatic impairment: No dosage adjustment required
<18 years: Safety and efficacy not established
Renal impairment or hemodialysis: No dosage adjustment required
Contraindicated for patients with hypersensitivity to Tedizolid and ingredients
Inhibits protein synthesis by binding with 50S ribosomal sub-unit in bacteria
Patients w/ neutropenia (neutrophil counts <1,000 cells/mm3). Discontinue if C. difficile-associated diarrhoea (CDAD) is suspected or confirmed. Patients w/ concomitant complicated skin & soft tissue infection & secondary bacteremia & in treatment of ABSSSI w/ severe sepsis or septic shock; diabetic foot infections, decubitus or ischaemic ulcers, bone or joint infections, severe burns, necrotizing infections or gangrene. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr. Elderly ≥75 yr.
2-10%\r\nNausea (8%)\r\nHeadache (6%)\r\nDiarrhea (4%)\r\nHemoglobin <10.1 g/dL (3.1%)\r\nVomiting (3%)\r\nPlatelets <112 x 10³/mm³ (2.3%)\r\nDizziness (2%)\r\n\r\n<2%\r\nBlood and lymphatic system disorders: Anemia\r\nCardiovascular: Palpitations, tachycardia\r\nEye disorders: Asthenopia, vision blurred, visual impairment, vitreous floaters\r\nGeneral disorders and administration site conditions: Infusion-related reactions\r\nImmune system disorders: Drug hypersensitivity\r\nInfections and infestations: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection\r\nInvestigations: Hepatic transaminases increased, decreased WBCs\r\nNervous system disorders: Hypoesthesia, paresthesia, seventh nerve paralysis\r\nPsychiatric disorders: Insomnia\r\nSkin and subcutaneous tissue disorders: Pruritus, urticaria, dermatitis\r\nVascular disorders: Flushing, hypertension
Increased AUC & Cmax of rosuvastatin. Inhibition of BCRP at the intestinal level, increased plasma conc of BCRP substrates, & the potential for adverse reactions especially for BCRP substrates w/ narrow therapeutic index (eg, methotrexate or topotecan), or rosuvastatin.
Acute bacterial skin and skin structure infections (ABSSSI)
Oral Administration\r\nMay take with or without food\r\n\r\nIV Administration\r\nAdminister as IV infusion over 1 hr\r\nDo NOT give as IV push or bolus\r\nNot for intra-arterial, IM, IT, intraperitoneal, or SC administration
Adult: 200 mg PO/IV once daily for 6 days\r\n\r\nHepatic impairment: No dosage adjustment required
<18 years: Safety and efficacy not established
Renal impairment or hemodialysis: No dosage adjustment required
Contraindicated for patients with hypersensitivity to Tedizolid and ingredients
Inhibits protein synthesis by binding with 50S ribosomal sub-unit in bacteria
Patients w/ neutropenia (neutrophil counts <1,000 cells/mm3). Discontinue if C. difficile-associated diarrhoea (CDAD) is suspected or confirmed. Patients w/ concomitant complicated skin & soft tissue infection & secondary bacteremia & in treatment of ABSSSI w/ severe sepsis or septic shock; diabetic foot infections, decubitus or ischaemic ulcers, bone or joint infections, severe burns, necrotizing infections or gangrene. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr. Elderly ≥75 yr.
2-10%\r\nNausea (8%)\r\nHeadache (6%)\r\nDiarrhea (4%)\r\nHemoglobin <10.1 g/dL (3.1%)\r\nVomiting (3%)\r\nPlatelets <112 x 10³/mm³ (2.3%)\r\nDizziness (2%)\r\n\r\n<2%\r\nBlood and lymphatic system disorders: Anemia\r\nCardiovascular: Palpitations, tachycardia\r\nEye disorders: Asthenopia, vision blurred, visual impairment, vitreous floaters\r\nGeneral disorders and administration site conditions: Infusion-related reactions\r\nImmune system disorders: Drug hypersensitivity\r\nInfections and infestations: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection\r\nInvestigations: Hepatic transaminases increased, decreased WBCs\r\nNervous system disorders: Hypoesthesia, paresthesia, seventh nerve paralysis\r\nPsychiatric disorders: Insomnia\r\nSkin and subcutaneous tissue disorders: Pruritus, urticaria, dermatitis\r\nVascular disorders: Flushing, hypertension
Increased AUC & Cmax of rosuvastatin. Inhibition of BCRP at the intestinal level, increased plasma conc of BCRP substrates, & the potential for adverse reactions especially for BCRP substrates w/ narrow therapeutic index (eg, methotrexate or topotecan), or rosuvastatin.






N/A





